Superhigh doses of dexamethasone in the treatment of refractory forms of acute lymphoblast leukemia of adults


Aim. Assessment of high-dose dexamethasone efficacy in combination with standard drugs (adriablatin,
vincristin, a-asparaginase) in patients with refractory acute lymphoblastic leukemia (ALE).
Material and methods. A pilot multicenter trial with participation of hematological departments of Hematological
Research Center (Moscow), municipal hospital N 1 (Krasnoyarsk), municipal hospital N\8
(Yaroslavl), Research Institute of Hematology and Blood Transfusion (Kirov) included 34 patients (jtQ
patients with late recurrences, 24 - with primary resistant forms, early and secondary recurrences)
Results. In patients with late ALL recurrences a complete remission (CR) was achieved in 70% cases,
the median being 10 months. In patients with primary resistant ALL, early and secondary recurrences
CR reached 37.5%, the median was 14 months.
Conclusion. The program HiDexa is highly effective : overall complete remission rate reached 47%,
median of complete remission duration was 10 months. Dexamethasone in high doses must be used only


  1. Hoeltier D., Gokbugen N. New approaches to acute lymphoblastic leukemia in adults: where do we go? Semin. Oncol. 2000; 27: 540-549.
  2. Larson R., Stock W., Hoeltzer D., Kantarjian H. Acute lymphoblastic leukemia in adults. Washington: ASH Educational Book; 1998. 44-62.
  3. Савченко В. Г., Исаев В. Г., Кучер Р. А. Программа RACOP в терапии острого лимфобластного лейкоза взрослых. В кн.: Материалы III Всесоюзного съезда гематологов и трансфузиологов. Киров; 1991. 186.
  4. Соколов А. Н. Лечение рецидивов и резистентных форм острых лейкозов: Дис... канд. мед. наук. М.; 2000.
  5. Kaspers G. J., Veerman A. J., Popp-Snijders C. et al. Comparison of the antileukemia activity in vitro of dexamethasone and prednisone in childhood acute lymphoblastic leukemia. Med. Pediatr. Oncol. 1996; 27 (2): 114-121.
  6. Put С. Н. Childhood leukemias. N. Engl. J. Med. 1995; 332: 1618-1630.
  7. Koller С. A., Kantarjian H., O'Brien S. et al. Hyper-CVAD regimen improves outcome in relapsed acute lymphoblastic leukemia. Blood 1997; 90 (10, suppl. I): abstr. 1482.

Copyright (c) 2021 Parovichnikova E.N., Savchenko V.G., Isaev V.G., Sokolov A.N., Moskov V.I., Klyasova G.A., Galtseva I.V., Ustinova E.N., Gribanova E.O., Lapin V.A., Zagoskina T.P.

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Address of the Editorial Office:

  • Novij Zykovskij proezd, 3, 40, Moscow, 125167

Correspondence address:

  • Alabyan Street, 13/1, Moscow, 127055, Russian Federation

Managing Editor:

  • Tel.: +7 (926) 905-41-26
  • E-mail:


© 2018-2021 "Consilium Medicum" Publishing house

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies